Committed to patients with AML—a disease area with high unmet need
Acute myeloid leukemia (AML) is a rare cancer of the blood and bone marrow characterized by rapid disease progression and proliferation of immature myeloid cells called myeloblasts. AML begins in the marrow, where new blood cells are made, but can quickly migrate to the blood and other areas of the body, including the lymph nodes, liver, spleen, central nervous system, and testicles. AML is a disease driven by genetic mutations. More than 99% of patients with AML have at least 1 mutation, and the majority have multiple mutations.
The annual incidence of AML in the United States alone is approximately 17,500, and in both the US and EU, approximately 31,000. AML mainly affects patients 68 and older. Despite scientific progress, disease prognosis remains poor, especially after relapse.
The Celgene Patient Commitment
Celgene is committed to researching and developing new options for patients affected by acute myeloid leukemia (AML) and other blood and hematologic malignancies.
Advocacy & Collaboration
Celgene remains committed to discovering new options for patients with AML and other hematologic malignancies: Bolder Science: Acute Myeloid Leukemia
Celgene is dedicated to offering support to patients with AML and those who care for them:
- A guide to supporting those with R/R AML can be found here.